Prestige Consumer Healthcare (PBH) Competitors

Prestige Consumer Healthcare logo
$49.38 +2.20 (+4.66%)
Closing price 03:59 PM Eastern
Extended Trading
$49.44 +0.06 (+0.12%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PBH vs. IPAR, HLF, USNA, NATR, and NUS

Should you buy Prestige Consumer Healthcare stock or one of its competitors? MarketBeat compares Prestige Consumer Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prestige Consumer Healthcare include Interparfums (IPAR), Herbalife (HLF), USANA Health Sciences (USNA), Nature's Sunshine Products (NATR), and Nu Skin Enterprises (NUS). These companies are all part of the "personal products" industry.

How does Prestige Consumer Healthcare compare to Interparfums?

Interparfums (NASDAQ:IPAR) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap personal products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Prestige Consumer Healthcare has lower revenue, but higher earnings than Interparfums. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Interparfums$1.49B2.32$168.39M$5.2720.50
Prestige Consumer Healthcare$1.09B2.15$190.30M$3.9112.63

Interparfums currently has a consensus target price of $106.00, suggesting a potential downside of 1.88%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 43.28%. Given Prestige Consumer Healthcare's higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Interparfums.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interparfums
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Prestige Consumer Healthcare has a net margin of 17.48% compared to Interparfums' net margin of 11.32%. Interparfums' return on equity of 15.47% beat Prestige Consumer Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Interparfums11.32% 15.47% 10.82%
Prestige Consumer Healthcare 17.48%11.54%6.16%

In the previous week, Prestige Consumer Healthcare had 1 more articles in the media than Interparfums. MarketBeat recorded 2 mentions for Prestige Consumer Healthcare and 1 mentions for Interparfums. Interparfums' average media sentiment score of 1.87 beat Prestige Consumer Healthcare's score of 0.29 indicating that Interparfums is being referred to more favorably in the media.

Company Overall Sentiment
Interparfums Very Positive
Prestige Consumer Healthcare Neutral

55.6% of Interparfums shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 43.7% of Interparfums shares are held by company insiders. Comparatively, 1.4% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Interparfums has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Summary

Interparfums beats Prestige Consumer Healthcare on 12 of the 17 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Herbalife?

Prestige Consumer Healthcare (NYSE:PBH) and Herbalife (NYSE:HLF) are both personal products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Prestige Consumer Healthcare has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Herbalife has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 5.1% of Herbalife shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Prestige Consumer Healthcare has a net margin of 17.48% compared to Herbalife's net margin of 4.67%. Prestige Consumer Healthcare's return on equity of 11.54% beat Herbalife's return on equity.

Company Net Margins Return on Equity Return on Assets
Prestige Consumer Healthcare17.48% 11.54% 6.16%
Herbalife 4.67%-41.47%8.24%

In the previous week, Prestige Consumer Healthcare had 1 more articles in the media than Herbalife. MarketBeat recorded 2 mentions for Prestige Consumer Healthcare and 1 mentions for Herbalife. Prestige Consumer Healthcare's average media sentiment score of 0.29 beat Herbalife's score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prestige Consumer Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Herbalife
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Prestige Consumer Healthcare currently has a consensus target price of $70.75, indicating a potential upside of 43.28%. Herbalife has a consensus target price of $17.80, indicating a potential upside of 42.40%. Given Prestige Consumer Healthcare's higher probable upside, research analysts plainly believe Prestige Consumer Healthcare is more favorable than Herbalife.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
Herbalife
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

Herbalife has higher revenue and earnings than Prestige Consumer Healthcare. Herbalife is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$1.09B2.15$190.30M$3.9112.63
Herbalife$5.04B0.26$228.30M$2.285.48

Summary

Prestige Consumer Healthcare beats Herbalife on 9 of the 16 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to USANA Health Sciences?

Prestige Consumer Healthcare (NYSE:PBH) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Prestige Consumer Healthcare has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, USANA Health Sciences has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Prestige Consumer Healthcare has a net margin of 17.48% compared to USANA Health Sciences' net margin of 0.96%. Prestige Consumer Healthcare's return on equity of 11.54% beat USANA Health Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Prestige Consumer Healthcare17.48% 11.54% 6.16%
USANA Health Sciences 0.96%6.21%4.50%

In the previous week, Prestige Consumer Healthcare and Prestige Consumer Healthcare both had 2 articles in the media. USANA Health Sciences' average media sentiment score of 0.71 beat Prestige Consumer Healthcare's score of 0.29 indicating that USANA Health Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prestige Consumer Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
USANA Health Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Prestige Consumer Healthcare has higher revenue and earnings than USANA Health Sciences. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$1.09B2.15$190.30M$3.9112.63
USANA Health Sciences$925.26M0.41$10.76M$0.4744.13

Prestige Consumer Healthcare presently has a consensus target price of $70.75, indicating a potential upside of 43.28%. Given Prestige Consumer Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than USANA Health Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
USANA Health Sciences
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 0.8% of USANA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Prestige Consumer Healthcare beats USANA Health Sciences on 12 of the 15 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Nature's Sunshine Products?

Nature's Sunshine Products (NASDAQ:NATR) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Prestige Consumer Healthcare has a net margin of 17.48% compared to Nature's Sunshine Products' net margin of 4.06%. Nature's Sunshine Products' return on equity of 14.67% beat Prestige Consumer Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Nature's Sunshine Products4.06% 14.67% 9.27%
Prestige Consumer Healthcare 17.48%11.54%6.16%

In the previous week, Nature's Sunshine Products had 2 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 4 mentions for Nature's Sunshine Products and 2 mentions for Prestige Consumer Healthcare. Nature's Sunshine Products' average media sentiment score of 0.75 beat Prestige Consumer Healthcare's score of 0.29 indicating that Nature's Sunshine Products is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nature's Sunshine Products
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Prestige Consumer Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Nature's Sunshine Products has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Nature's Sunshine Products presently has a consensus target price of $35.00, suggesting a potential upside of 66.75%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 43.28%. Given Nature's Sunshine Products' stronger consensus rating and higher probable upside, equities research analysts plainly believe Nature's Sunshine Products is more favorable than Prestige Consumer Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nature's Sunshine Products
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Prestige Consumer Healthcare has higher revenue and earnings than Nature's Sunshine Products. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nature's Sunshine Products$489.79M0.75$19.52M$1.1019.08
Prestige Consumer Healthcare$1.09B2.15$190.30M$3.9112.63

79.4% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 3.1% of Nature's Sunshine Products shares are owned by insiders. Comparatively, 1.4% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Nature's Sunshine Products beats Prestige Consumer Healthcare on 9 of the 15 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Nu Skin Enterprises?

Prestige Consumer Healthcare (NYSE:PBH) and Nu Skin Enterprises (NYSE:NUS) are both personal products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Prestige Consumer Healthcare has higher earnings, but lower revenue than Nu Skin Enterprises. Nu Skin Enterprises is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$1.09B2.15$190.30M$3.9112.63
Nu Skin Enterprises$1.49B0.17$160.20M$1.104.78

Prestige Consumer Healthcare presently has a consensus target price of $70.75, suggesting a potential upside of 43.28%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, equities analysts plainly believe Prestige Consumer Healthcare is more favorable than Nu Skin Enterprises.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
Nu Skin Enterprises
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

In the previous week, Prestige Consumer Healthcare had 2 more articles in the media than Nu Skin Enterprises. MarketBeat recorded 2 mentions for Prestige Consumer Healthcare and 0 mentions for Nu Skin Enterprises. Prestige Consumer Healthcare's average media sentiment score of 0.29 beat Nu Skin Enterprises' score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company Overall Sentiment
Prestige Consumer Healthcare Neutral
Nu Skin Enterprises Neutral

Prestige Consumer Healthcare has a net margin of 17.48% compared to Nu Skin Enterprises' net margin of 3.78%. Prestige Consumer Healthcare's return on equity of 11.54% beat Nu Skin Enterprises' return on equity.

Company Net Margins Return on Equity Return on Assets
Prestige Consumer Healthcare17.48% 11.54% 6.16%
Nu Skin Enterprises 3.78%7.47%4.21%

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 82.8% of Nu Skin Enterprises shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 2.8% of Nu Skin Enterprises shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Prestige Consumer Healthcare has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Nu Skin Enterprises has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

Prestige Consumer Healthcare beats Nu Skin Enterprises on 13 of the 16 factors compared between the two stocks.

Get Prestige Consumer Healthcare News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBH vs. The Competition

MetricPrestige Consumer HealthcareMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$2.34B$8.46B$6.81B$23.29B
Dividend YieldN/A2.54%2.68%4.11%
P/E Ratio12.6315.9125.7931.66
Price / Sales2.155.79548.6320.32
Price / Cash9.0917.1646.3324.53
Price / Book1.243.3610.774.74
Net Income$190.30M$226.25M$3.57B$1.07B
7 Day Performance5.08%0.44%3.15%0.99%
1 Month Performance2.76%-1.88%2.34%0.96%
1 Year Performance-39.18%0.69%33.41%24.40%

Prestige Consumer Healthcare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBH
Prestige Consumer Healthcare
3.4198 of 5 stars
$49.38
+4.7%
$70.75
+43.3%
-42.4%$2.34B$1.09B12.63540
IPAR
Interparfums
3.6263 of 5 stars
$99.70
+0.3%
$106.00
+6.3%
-21.6%$3.18B$1.49B18.82530
HLF
Herbalife
4.2931 of 5 stars
$11.99
+0.1%
$17.80
+48.5%
+45.9%$1.24B$5.04B5.268,500
USNA
USANA Health Sciences
2.5759 of 5 stars
$19.45
+0.2%
N/A-35.8%$359.07M$925.26M41.391,570
NATR
Nature's Sunshine Products
3.7821 of 5 stars
$20.22
+0.9%
$35.00
+73.1%
+39.3%$355.36M$480.14M18.38850

Related Companies and Tools


This page (NYSE:PBH) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners